Geron (NASDAQ:GERN) Price Target Lowered to $4.00 at Stifel Nicolaus

Geron (NASDAQ:GERN) had its price objective reduced by Stifel Nicolaus from $8.00 to $4.00 in a research report report published on Thursday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the biopharmaceutical company’s stock.

GERN has been the subject of several other research reports. Barclays reissued an “overweight” rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a research report on Thursday. Needham & Company LLC dropped their target price on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and cut their target price for the stock from $3.50 to $2.00 in a research report on Thursday. Finally, HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Price Performance

Shares of GERN stock opened at $1.74 on Thursday. Geron has a 12 month low of $1.46 and a 12 month high of $5.34. The company has a market capitalization of $1.05 billion, a P/E ratio of -5.44 and a beta of 0.53. The stock has a 50 day moving average of $2.97 and a two-hundred day moving average of $3.80. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $47.54 million during the quarter, compared to analysts’ expectations of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. As a group, equities analysts expect that Geron will post -0.25 EPS for the current year.

Institutional Investors Weigh In On Geron

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GERN. SBI Securities Co. Ltd. bought a new stake in shares of Geron during the fourth quarter valued at approximately $28,000. Integrated Wealth Concepts LLC acquired a new position in Geron during the 4th quarter worth $36,000. GF Fund Management CO. LTD. bought a new position in Geron in the 4th quarter valued at $45,000. Fifth Lane Capital LP acquired a new stake in shares of Geron in the 4th quarter valued at $53,000. Finally, Readystate Asset Management LP bought a new stake in shares of Geron during the third quarter worth $58,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.